{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-022067","form_type":"8-K","ticker":"CODX","cik":"0001692415","company_name":"Co-Diagnostics, Inc.","filed_at":"2022-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.681949+00:00","generated_at":"2026-06-24T00:55:33.798657+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Co-Diagnostics Q2 2022 revenue $5.0M, down 82% YoY; net loss $2.7M","bullets":["Revenue of $5.0M vs $27.4M a year ago; gross profit margin 81.8% due to sales volume inefficiencies.","Net loss of $2.7M ($0.08 loss per diluted share) compared to net income of $9.8M in Q2 2021.","Operating loss of $4.1M vs operating income of $11.8M; adjusted EBITDA loss $2.3M.","Cash, equivalents, and marketable securities at $96.0M as of June 30, 2022.","Business highlights: Indian JV CoSara cleared for Hepatitis C test; monkeypox test reagents shipped; Co-Dx PCR Home platform optimization continues."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-022067","json":"https://secwatch.observer/filing/0001493152-22-022067.json","markdown":"https://secwatch.observer/filing/0001493152-22-022067.md","text":"https://secwatch.observer/filing/0001493152-22-022067.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1692415/000149315222022067/0001493152-22-022067-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1692415/000149315222022067/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T00:55:33.798657+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}